1-7 of 7
Sorin Visanica, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available

Lynda Foltz, MD FRCPC, Gian-Matteo Pica, MD, Hacene Zerazhi, Jan Van Droogenbroeck, MD, Sorin Visanica, MD, Enrique Báez de la Fuente, MD, Brian Leber, MD, Antonio Medina de Almeida, MD PhD, Dana Ranta, MD, Mauricio Reyes Cartes, MD, Jean-Jacques Kiladjian, MD PhD, Linda Chrit, PhD, Zhaoyu Yin, PhD, Juliane Morando, MD, Timothy Devos
Journal: Blood
Blood (2018) 132 (Supplement 1): 1774.
https://doi.org/10.1182/blood-2018-99-111479
Published: 2018
Journal Articles

Personalized Daily Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia. Final Results of the Randomized OPTIM Imatinib Study

Philippe Rousselot, MD PhD, Hyacinthe Johnson-Ansah, MD, Françoise Huguet, MD, Laurence Legros, MD, Martine Escoffre-Barbe, Martine Gardembas, MD, Pascale Cony-Makhoul, MD, Valérie Coiteux, MD, Laurent Sutton, MD, Wajed Abarah, MD, Camille Pouaty, MD, Jean Michel Pignon, MD, Bachra Choufi, MD, Sorin Visanica, MD, Bénédicte Deau, MD, Stephane Bouchet, MDPhD, Francois Guilhot, MD, Francois-Xavier Mahon, MD PhD Professor, Laure Morisset, Jean-Michel Cayuela, Benjamin Maneglier, MD
Journal: Blood
Blood (2015) 126 (23): 133.
https://doi.org/10.1182/blood.V126.23.133.133
Published: 2015
Journal Articles

Ruxolitinib Therapy in Myelofibrosis: Analysis of 241 Patients Treated in Compassionate Use (French “ATU” program) by the French Intergroup of Myeloproliferative Neoplasms (FIM).

Annalisa Andreoli, MD, Jerome Rey, MD, Charles Dauriac, MD, Raoul Herbrecht, MD, Franck E. Nicolini, MD, PhD, Christian Recher, MD, PhD, Philippe Rousselot, MD, PhD, Jacques Delaunay, MD, Bernard Drenou, MD, PhD, Dana Ranta, MD, Laurence Legros, MD, PhD, Martine Delain, MD, Pascale Cony-Makhoul, MD, Jean-François Viallard, MD, PhD, Sorin Visanica, MD, Sophie Lefort, MD, Brigitte Dupriez, MD, Valérie Coiteux, MD, Denis Guyotat, MD, Borhane Slama, MD, Khaled Benabed, MD, Jean-Loup Demory, MD, Stephane Giraudier, MD, PhD, Damien Roos-Weil, MD, Laurence Sanhes, MD, Anne Quinquenel, MD, Pascal Lenain, MD, Valérie Ugo, MD, PhD, Jean-Jacques Kiladjian, MD, PhD, Lydia Roy, MD
Journal: Blood
Blood (2012) 120 (21): 2841.
https://doi.org/10.1182/blood.V120.21.2841.2841
Published: 2012
Journal Articles

Is Azacitidine (AZA) Really Effective in High Risk MDS Patients with Chromosome 7 Abnormalities (Abn 7)? Results of a Retrospective Study From the GFM and GESMD Registries

María Díez-Campelo, MD, PhD, Raphael Itzykson, Silvia M Rojas, Céline Berthon, MD, PhD, Elisa Luño, Odile Beyne-Rauzy, Jaime Perez-Oteyza, Norbert Vey, MD, PhD, Joan Bargay, Sophie Park, Teresa Cedena, Dominique Bordessoule, MD, PhD, Juan A Muñoz, Emmanuel Gyan, MD, PhD, Esperanza Such, Sorin Visanica, MD, Luis Benlloch, Stéphane de Botton, MD, PhD, Jesús M Hernández-Rivas, Shanti Ame, MD, Aspasia Stamatoullas, MD, Jacques Delaunay, MD, Celia Salanoubat, MD, Françoise Isnard, MD, Guillermo Sanz, Romain Guieze, MD, Consuelo Cañizo, MD, PhD, Pierre Fenaux, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1713.
https://doi.org/10.1182/blood.V120.21.1713.1713
Published: 2012
Journal Articles

Azacytidine in Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results of the French ATU Program.

Raphael Itzykson, Sylvain Thépot, Christian Recher, Jacques Delaunay, MD, Bruno Quesnel, Francois Dreyfus, MD, PhD, Anne Marfaing Koka, Norbert Vey, Aspasia Stamatoullas, Emmanuel Gyan, MD, Thomas Cluzeau, Philippe Rousselot, MD, PhD, Oumedaly Reman, Isabelle Plantier, Jean Pierre Marolleau, MD, Pierre Morel, MD, Eric Wattel, MD, PhD, Sorin Visanica, MD, Chahinez Zerhouni, Dominique Bordessoule, Lionel Ades, MD, Pierre Fenaux, Claude Gardin
Journal: Blood
Blood (2009) 114 (22): 1054.
https://doi.org/10.1182/blood.V114.22.1054.1054
Published: 2009
Journal Articles

Prognostic Factors of Response and Overall Survival (OS) in Higher-Risk MDS (including RAEB-t) Treated with Azacytidine (AZA): Results of the French ATU Program.

Raphael Itzykson, Sylvain Thépot, Bruno Quesnel, Odile Beyne-Rauzy, MD, PhD, Francois Dreyfus, MD, PhD, Norbert Vey, MD, Pascal Turlure, MD, Laurence Legros, Caroline Dartigeas, Jacques Delaunay, MD, Stephane de Botton, MD, PhD, Emmanuel Raffoux, MD, Anne-Laure Taksin, MD, Aspasia Stamatoullas, Anne Marfaing Koka, Eric Wattel, MD, PhD, Sorin Visanica, MD, Célia Salanoubat, Pierre Morel, MD, Pascale Cony Makhoul, Stéphane Cheze, Laurence Sanhes, Isabelle Plantier, Gerard Tertian, Mehdi Dahoun, Agnes Guerci, MD, PhD, Claude Gardin, Lionel Ades, MD, Pierre Fenaux
Journal: Blood
Blood (2009) 114 (22): 3820.
https://doi.org/10.1182/blood.V114.22.3820.3820
Published: 2009
Journal Articles

Treatment of Lower Risk MDS with Del 5q with Lenalidomide (LEN): Results of the French ATU Program.

Fabien Le bras, MD, Marie Sebert, MD, Charikleia Kelaidi, MD, Thierry Lamy, MD, PhD, Francois Dreyfus, MD, PhD, Jacques Delaunay, MD, Anne Banos, MD, Michel Blanc, MD, Norbert Vey, MD, PhD, Martine Gardembas, MD, Sorin Visanica, MD, Frederic Bauduer, MD, Pascal Turlure, MD, Mehdi Dahoun, Odile Beyne-Rauzy, MD, PhD, Agnes Guerci, MD, PhD, Alain Delmer, MD, PhD, Stephane de Botton, MD, PhD, Christian Berthou, MD, Caroline Besson, MD, Delphine Rea, MD, PhD, Francois Lefrere, MD, Eric Wattel, MD, PhD, Philippe Rousselot, MD, PhD, Pierre Fenaux, MD, PhD, Lionel Ades, MD
Journal: Blood
Blood (2009) 114 (22): 2764.
https://doi.org/10.1182/blood.V114.22.2764.2764
Published: 2009